45
Views
2
CrossRef citations to date
0
Altmetric
Editorial

Toward effective prescription of inhaled corticosteroids in chronic airway disease

, &
Pages 3419-3424 | Published online: 18 Oct 2018

The airway diseases asthma and COPD affect millions of individuals worldwide.Citation1 These diseases are major determinants of chronic morbidity and mortality, and represent a substantial public health burden.Citation2Citation4 Despite differences in etiology, clinical characteristics, and pathophysiology, both conditions share important features, such as airway obstruction and chronic airway inflammation. As a result of modern lifestyle, the incidence of both diseases is steadily increasing worldwide and effective preventive and treatment strategies are unmet needs.Citation5

Traditionally, airway eosinophilia has been regarded as a major hallmark of asthma, whereas COPD has been associated with neutrophilic airway inflammation.Citation6 For treatment of chronic inflammatory airway diseases, inhaled corticosteroids (ICS) are usually prescribed as maintenance therapy, most often as part of a combination therapy. While the majority of asthma patients generally respond well to ICS,Citation7 this is not often the case in COPD.Citation8 Hence, reliable algorithms and easily implemented tools are needed to identify ICS responders in clinical practice, to optimize clinical benefits and minimize adverse events.

Over the past two decades, increasing insights into the pathobiology of chronic airway disease have enabled an understanding of its heterogeneous nature and thus helped to shape precision medicine.Citation9 These novel insights are gradually being adapted by (inter)national guidelines for disease management in daily practice. In asthma, this has – among others – resulted in adding targeted therapies with biologicals for refractory allergic and/or eosinophilic asthma at treatment step 5 and, more recently, in adding house dust mite (HDM) sublingual immunotherapy for HDM-sensitized asthma patients uncontrolled on standard therapy in steps 3 and 4.Citation3

Until recently, the Global Initiative for Obstructive Lung Disease (GOLD) strategy did not differentiate across the COPD spectrum.Citation10 For example, the GOLD-D category comprised three different phenotypes, ie, patients with a severe airway obstruction or frequent exacerbations, or both. Recent advances have led to the recognition that these different subsets may require different treatment approaches instead of the “one-size fits all” ICS-containing therapy as advocated in the treatment strategy at that time.Citation10 This has resulted in default prescription of ICS for COPD patients.Citation8

Increasing evidence of limited clinical effectiveness in distinct phenotypes,Citation11Citation14 along with safety concerns associated with long-term use of high-dose ICS,Citation15,Citation33 has driven a personalized treatment strategy for chronic inflammatory airway disease recently proposed by an international expert panel.Citation16

Precision medicine is the cornerstone of this innovative approach advocating identification and treatment of “treatable traits” in individual patients.Citation17,Citation18 In this context, blood eosinophils as indicators of eosinophilic exacerbations have been identified as a “treatable trait”.Citation19,Citation20 Data from several studies showed that benefits from ICS in COPD were limited to patients with frequent exacerbations and blood eosinophilia (the higher the initial blood eosinophil count the more the benefit).Citation13,Citation21 The recently updated GOLD classification is based on symptoms and exacerbations and hence provides a more differentiated treatment algorithm.Citation22 Consequently, ICS therapy is only recommended for patients with frequent exacerbations uncontrolled on a combination of bronchodilators (ie, GOLD C and D).Citation22 In this paper, we will provide a rationale toward more effective ICS prescription for patients with chronic inflammatory airway disease based on treatable traits.

Over-prescription of inhaled corticosteroids in chronic inflammatory airway disease

ICS have been available to treat chronic inflammatory airway disease for almost 70 years.Citation23 Consequently, ICS-containing treatments have been amongst the most commonly prescribed and thus most profitable medications.Citation24 This has enabled pharmaceutical companies to further develop this area of therapeutics. However, despite a massive level of prescription of (optimized) ICS and long-acting beta-agonist (LABA) combinations, many patients remain suboptimally controlled,Citation25,Citation26 with only small changes in morbidity and mortality of both asthma and COPD, while numbers of hospital admissions continue to rise increasing health care costs as a consequence.Citation27 Although this may partly be ascribed to an increase in the prevalence of both conditions, we cannot attribute the clinical reality to this factor alone. Is it possible that many of the patients treated with ICS are either non-responsive or respond suboptimally to this treatment?

Dogmatic prescription of ICS in chronic airway disease has resulted in a significant level of over-prescription.Citation28 In asthma, awareness of the potential for a customized approach to ICS prescription has been incorporated into the guidelines advocating a step-down regime after control has been reached. Moreover, guidelines now accept a role for a more flexible maintenance and rescue from the use of ICS/LABA combinations.Citation29 In COPD, the efficacy of ICS therapy has been investigated for over 25 years now. Initially, it was assumed that the benefits seen in many asthma patients would be transferrable to those with COPD. Large scale studies were performed with high doses of ICS, all of which were either negative or demonstrated modest benefits at best.Citation30 No protection was observed against a decline in lung function and overall, only modest effects on exacerbations and quality of life were seen.Citation31 Despite these findings, in clinical practice, ICS continued to be prescribed to COPD patients at every level of lung function deficit and for every disease category as defined by the GOLD approach.Citation8 Moreover, ICS are prescribed for at least 40% of smokers presenting with symptoms without any measurable lung function abnormality.Citation28,Citation32 In these individuals, there is no evidence to support the use of ICS.

The results of the over-prescription of ICS affect all parties involved. First, the individuals treated erroneously are being exposed to medication they do not actually need along with the potential for side effects (eg, oropharyngeal candidiasis, dysphonia, skin bruising, osteoporosis, cataract, loss of diabetic control, and pneumonia).Citation33Citation35 Second, the prescribers feel that they are treating their patient and thus do not reflect on other – more effective – therapies, and, finally, the insurance ends up paying for ineffective medication and is thus unable to fund much more cost-effective approaches in the long term (smoking cessation, bronchodilators, pulmonary rehabilitation).

Prescribing ICS on a “one size fits all basis” could be justified in the early years because this was the only available medication option. Presently, prescribing by default is no longer acceptable and a more personalized approach based on treatable traits should be encouraged.

From “one size fits all” toward personalized treatment

In many ways, proposing a more precise approach to the prescription of ICS may seem contradictory, as corticosteroids are a non-precise treatment by their very mechanism of action. Nevertheless, it is crucial for physicians to appropriately prescribe ICS to ensure effectiveness and limit side effects. Both for asthma and COPD, utilizing biomarkers has been shown to aid the diagnosis, to predict exacerbations and to drive treatment.Citation36,Citation37 In this respect, fractionated exhaled nitric oxide (FeNO) and blood eosinophils are easily measurable biomarkers that can be used to predict and to monitor treatment response and adherence to ICS.Citation16,Citation38,Citation39

Currently, there is increasing understanding that both asthma and COPD are heterogeneous disorders with overlapping characteristics.Citation3,Citation9,Citation18 Even though at times they may appear to be clinically indistinguishable, cluster analyses have identified distinct clinical, biological, and pathological clusters with different responses to treatment.Citation7,Citation20,Citation40Citation43 Importantly, cluster analyses can link inflammatory phenotypes to treatment algorithms. For instance, the hierarchical cluster analysis by Haldar et al on data from over 400 asthma patients revealed five different phenotypic clusters based on concordance between symptoms, sputum eosinophilia, and the response to ICS.Citation7

Patients with concordant symptoms and sputum eosinophilia presented with milder, often atopic disease, with an overall good response to ICS and a benign disease course, while those with discordant symptoms or inflammation usually presented with a more complex disease with varying response to ICS. Similar observations have been previously made in a number of clinical studies.Citation44,Citation45 Overall, these findings support a symptom-guided approach to management for mild to moderate, “concordant”-type asthma, while “discordant”-type, refractory asthmatics might benefit from inflammatory biomarker-guided, personalized therapeutic options including targeted therapy with biologics.

How do these findings relate to COPD? ISOLDE was one of the first studies to investigate the effect of ICS on the rate of decline in lung function in COPD patients. The study was negative for its primary end point.Citation31 However, data from a post hoc analysis of the ISOLDE study revealed that patients with moderate to severe COPD with persistent blood eosinophilia of ≥2% show an accelerated lung function decline that can be prevented by ICS treatment, while ICS did not affect lung function decline in patients with blood eosinophila <2%.Citation46 This compelling evidence in combination with novel insights into underlying disease mechanisms urged a panel of international experts to propose a personalized approach to chronic inflammatory airway disease management beyond clinical labels.Citation17,Citation18 Hence, the concept of “treatable traits” was conceived, implementing precision medicine into clinical practice.

These insights based on emerging data from large clinical trials helped to further shape the updated GOLD strategy.Citation22 This update has reclassified COPD and emphasizes the dual goals of symptom control and reduction in risk of exacerbation. Presently, optimal bronchodilator therapy, often comprising a LABA with a long-acting muscarinic antagonist (LAMA) in a fixed dose combination (FDC), is the cornerstone of COPD treatment.Citation22 This combination treatment decreases both the static and dynamic hyperinflation, which helps to optimize lung function, daily activities, to improve exercise capacity and endurance, and the overall quality of life.Citation47Citation49 LABA–LAMA bronchodilator combination therapy has been recommended based on the outcomes of large randomized controlled trials including the recently published FLAME study.Citation50 This large prospective study showed superiority of the LABA–LAMA combination in preventing exacerbations in patients with COPD as compared to those on a fixed ICS–LABA combination, irrespective of baseline blood eosinophils.Citation51 The study had tightly controlled inclusion criteria which excluded participants with baseline eosinophils >600 cells/µL, and the run-in period excluded ICS with the potential that eosinophilic participants will become unstable and be excluded. During this 52-week study, the incidence of pneumonia was significantly higher in patients on ICS–LABA compared to those on LABA–LAMA combination (4.8% vs 3.2%, p=0.02). These findings are in line with previous large studies investigating the effect of ICS (containing) therapy on exacerbations, lung function decline, and mortality in COPD which could not demonstrate substantial or additional clinical benefits of ICS in many patients over time.Citation31,Citation51Citation54 Several other studies have examined the risk benefit of the use of ICS and also ICS withdrawal.Citation16,Citation53Citation59 Specifically, during the 12-month study (WISDOM) that included patients with (very) severe COPD taking tiotropium plus salmeterol, the risk of moderate or severe exacerbations was similar among those who discontinued ICS and those on ICS co-treatment.Citation52 A recent post hoc analysis showed that only patients with at least one exacerbation in the previous year and a high blood eosinophil count (ie, ≥300 cells/µL or ≥4%) at baseline were at increased risk of an exacerbation after complete ICS withdrawal, representing a minority of the entire study population (n=2296).Citation58 Indeed, other studies confirmed that blood eosinophils may further help to identify COPD patients with frequent exacerbations as a distinct phenotype that may benefit from ICS, while eosinophilic airway inflammation has been proposed as a “treatable trait”.Citation8,Citation17,Citation20,Citation59

Consequently, it is crucial to critically assess the benefits versus risks in the individual COPD patient and positively prescribe ICS based on phenotype-related treatable traits.Citation17,Citation18 The updated GOLD strategy now better reflects this personalized approach.Citation22

Changing of guidelines?

The future management of inflammatory airways disease is potentially very exciting. We believe that given the ample supportive evidence, which is shaping the current guidelines, the journey toward a “treatable trait” approach can really start. Our goal must be to give more effective therapy to patients who will respond – this applies not only to targeted treatments with biologic agents or small molecules but also existing therapy with ICS – and thus improve disease outcome while reducing the side effects of unnecessary pharmacotherapy. An aspirational goal should be to never have to prescribe oral corticosteroids again to any patient with a proven inflammatory airways disease.Citation16

To be able to move forward, we need to have a clear and accurate diagnosis. Focusing on obtaining information as to the individual patient’s symptoms, comorbidities and pathophysiology (clinical phenotype) complemented with the inflammatory phenotype. Based on these individual characteristics, the correct treatment can be initiated. Presently, ICS with or without the addition of LABA are considered the basis of asthma pharmaceutical treatment. Comorbidities should be treated, and treatment should be adjusted/reconsidered with the goal of achieving optimal control of symptoms, reducing the risk of acute exacerbations and improving the patient’s daily activities/quality of life.

COPD treatment goals are similar: improving symptoms (dyspnea), reducing the risk of acute exacerbations, and improving quality of life. Apart from pharmacotherapy, non-drug treatment modalities are helpful to achieve optimal outcomes in COPD patients. Smoking cessation is essential in combination with bronchodilator therapy, to improve dyspnea, while the opportunity for pulmonary rehabilitation should not be missed. Although challenging to many patients, pulmonary rehabilitation and necessary lifestyle adjustments are often critical to improve and reverse loss of lung function and exercise endurance. Bronchodilator therapy in COPD should always be optimized, ie, a combination of a LAMA and a LABA, now available as a FDC. Finally, based on the clinical phenotype stratification according to GOLD, we should make further treatment decisions based upon a detailed assessment of the underlying inflammatory mechanisms (inflammatory phenotype). Clinical (GOLD) phenotype should, at present, be given primacy when making decisions to intensify therapy – especially moving triple therapy with ICS – as we lack definitive prospective data as to the utility of a true focused “treatable trait” prescription approach. However, it is clear that simply measurable and available biomarkers such as FeNO and blood eosinophil counts may help to predict a favorable response to ICS not only in asthma but also in COPD. More biomarkers will emerge and the use of a composite approach may have even more clinical utility, leading to mechanistic insights as well as directing disease modifying therapy such as new biological agents and small molecule inhibitors of specific inflammatory pathway targets.

In summary, our goals for patients with asthma should be: to have minimal (none) symptoms, be free of restrictions in daily activities, and patients should never die of their disease. All patients should have their treatment titrated to the lowest level required to achieve and maintain these goals. COPD patients should be treated with the goal of reversing the disability that years of accelerated lung function decline have caused with a reduction in risk of exacerbations. This will be best achieved by a personalized approach, leading to an individual understanding of risks and benefits. The correct treatments should be given to the patients who will achieve the maximum benefit with the minimum risk. With current therapies, such management goals are within our grasp, although taking an individualized approach to management will maximize benefit and minimize risk.

Disclosure

The authors report no conflicts of interest in this work.

References

  • MurrayCJLLopezADMeasuring the global burden of diseaseN Engl J Med2013369544845723902484
  • BatemanEDHurdSSBarnesPJGlobal strategy for asthma management and prevention: GINA executive summaryEur Respir J200831114317818166595
  • 2018 GINA Report, Global Strategy for Asthma Management and Prevention Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/Accessed April 24, 2018
  • VogelmeierCFCrinerGJMartinezFJChronic obstructive pulmonary diseaseEur Respir J2017121433438
  • SorianoJBAbajobirAAAbateKHGlobal, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015Lancet Respir Med20175969170628822787
  • KeatingsVMBarnesPJGranulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjectsAm J Respir Crit Care Med199715524494539032177
  • HaldarPPavordIDShawDECluster analysis and clinical asthma phenotypesAm J Respir Crit Care Med2008178321822418480428
  • BrusselleGPriceDGruffydd-JonesKThe inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInt J Chron Obstruct Pulmon Dis2015102207221726527869
  • SterkPJChronic diseases like asthma and COPD: do they truly exist?Eur Respir J201647235936126828042
  • GOLD COPD Strategy2014 Available from: www.GOLDCOPD.orgAccessed April 24, 2018
  • PereraWRHurstJRWilkinsonTMAInflammatory changes, recovery and recurrence at COPD exacerbationEur Respir J200729352753417107990
  • WedzichaJAAntibiotics at COPD exacerbations: the debate continuesThorax2008631194094218984809
  • WillsonJBatemanEDPavordILloydAKrivasiTEsserDCost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonistsAppl Health Econ Health Policy201412444745924974107
  • MagnussenHTetzlaffKCalverleyPMAInhaled glucocorticoids and COPD exacerbationsN Engl J Med201537219394
  • PriceDBRussellRMaresRMetabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort studyPLoS One2016119e016290327658209
  • PavordIDBeasleyRAgustiAAfter asthma: redefining airways diseasesLancet20183911011835040028911920
  • AgustiABelEThomasMTreatable traits: toward precision medicine of chronic airway diseasesEur Respir J201647241041926828055
  • AgustiABafadhelMBeasleyRPrecision medicine in airway diseases: moving to clinical practiceEur Respir J2017504pii: 1701655
  • BafadhelMGreeningNJHarvey-DunstonTSevere hospitalised exacerbations of COPD with an eosinophilic phenotype have favourable outcomes with prednisolone therapy sub-analysis from a prospective multi-centre randomised control trialThorax201368Suppl IIIA16
  • BafadhelMMcKennaSTerrySAcute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkersAm J Respir Crit Care Med2011184666267121680942
  • PavordIDLettisSLocantoreNBlood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPDThorax201671211812526585525
  • GOLD 2018 Global Strategy for the Diagnosis, Management and Prevention of COPD Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/Accessed April 24, 2018
  • GelfandMLAdministration of cortisone by the aerosol method in the treatment of bronchial asthmaN Engl J Med1951245829329414863574
  • MoonJCFlettASGodmanBBGrossoAMWierzbickiASGetting better value from the NHS drug budgetBMJ2010341c644921169320
  • BatemanEDBousheyHABousquetJCan guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL studyAm J Respir Crit Care Med2004170883684415256389
  • RabeKFVermeirePASorianoJBMaierWCClinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) studyEur Respir J200016580280711153575
  • SurukiRYDaughertyJBBoudiafNAlbersFCThe frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USABMC Pulm Med20171717428449686
  • PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990425210450
  • LevyMLThomasMSmallIPearceLPinnockHStephensonPSummary of the 2008 BTS/SIGN British Guideline on the management of asthmaPrim Care Respir J200918Suppl 1S1S1619209371
  • FordPARussellREBarnesPJICS and COPD: time to clear the airInt J Chron Obstruct Pulmon Dis2009428929019684862
  • BurgePSCalverleyPMJonesPWSpencerSAndersonJAMaslenTKRandomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ200032072451297130310807619
  • WhitePThorntonHPinnockHGeorgopoulouSBoothHPOver-treatment of COPD with inhaled corticosteroids –iImplications for safety and costs: cross-sectional observational studyPLoS One2013810e7522124194824
  • SuissaSKezouhAErnstPInhaled corticosteroids and the risks of diabetes onset and progressionAm J Med2010123111001100620870201
  • SuissaSBarnesPJInhaled corticosteroids in COPD: the case againstEur Respir J2009341131619567599
  • PriceDBRussellRMaresRMetabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort studyPLoS One2016119e016290327658209
  • DiamantZBootJDMantzouranisEFlohrRSterkPJGerth van WijkRBiomarkers in asthma and allergic rhinitisPulm Pharmacol Ther201023646848120601050
  • ParulekarADDiamantZHananiaNARole of T2 inflammation biomarkers in severe asthmaCurr Opin Pulm Med2016221596826574724
  • MartinMJWilsonEGerrard-TarpeyWThe utility of exhaled nitric oxide in patients with suspected asthmaThorax201671656256426903595
  • BafadhelMPavordIDRussellREKEosinophils in COPD: just another biomarker?Lancet Respir Med20175974775928601554
  • BurgelP-RPaillasseurJ-LPeeneBTwo distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortalityPLoS One2012712e5104823236428
  • MooreWCMeyersDAWenzelSEIdentification of asthma phenotypes using cluster analysis in the Severe Asthma Research ProgramAm J Respir Crit Care Med2010181431532319892860
  • Sendin-HernandezMPAvila-ZarzaCSanzCIdentification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysisAm J Respir Crit Care Med20177216372
  • WeatherallMTraversJShirtcliffePMDistinct clinical phenotypes of airways disease defined by cluster analysisEur Respir J200934481281819357143
  • GreenRHBrightlingCEMcKennaSAsthma exacerbations and sputum eosinophil counts: a randomised controlled trialLancet200236093471715172112480423
  • WoodruffPGModrekBChoyDFT-helper type 2-driven inflammation defines major subphenotypes of asthmaAm J Respir Crit Care Med2009180538839519483109
  • BarnesNCSharmaRLettisSCalverleyPMABlood eosinophils as a marker of response to inhaled corticosteroids in COPDEur Respir J20164751374138226917606
  • Di MarcoFSotgiuGSantusPLong-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysisRespir Res20181911829368604
  • BuhlRGessnerCSchuermannWEfficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority studyThorax201570431131925677679
  • BeehK-MWestermanJKirstenA-MThe 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary diseasePulm Pharmacol Ther201532535925956072
  • WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
  • RocheNChapmanKRVogelmeierCFBlood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. data from the FLAME trialAm J Respir Crit Care Med201719591189119728278391
  • MagnussenHWatzHKirstenAStepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationaleRespir Med2014108459359924477080
  • MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
  • SuissaSRossiAWeaning from inhaled corticosteroids in COPD: the evidenceEur Respir J20154651232123526521271
  • RossiAvan der MolenTdel OlmoRINSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPDEur Respir J20144461548155625359348
  • WoutersEFMPostmaDSFokkensBWithdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trialThorax200560648048715923248
  • van der ValkPMonninkhofEvan der PalenJZielhuisGvan HerwaardenCEffect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE studyAm J Respir Crit Care Med2002166101358136312406823
  • WatzHTetzlaffKWoutersEFMBlood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialLancet Respir Med20164539039827066739
  • PavordIDLettisSAnzuetoABarnesNBlood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysisLancet Respir Med20164973174127460163